Ad5-EBOV is a adenovirus type 5 vector based Ebola virus disease vaccine, a vaccine jointly developed by, among others, CanSinoBio, that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector to induce the immune response. It received the NDA approval in China in October 2017. 

Our Ad5-EBOV is the first approved Ebola virus vaccine in China for emergency use and national stockpile. The development and approval of Ad5-EBOV demonstrates our capabilities to efficiently advance a vaccine candidate from R&D stage to an approved product using our platform technology and to manufacture safe and effective vaccine products. As compared to competing products from multinational companies, our Ad5-EBOV has shown a better stability profile and does not require ultra-low temperature storage conditions. Our Ad5-EBOV is currently for national stockpile and has potential for international stockpile opportunities.